1. All ESRD treatment is expensive and a modality change adds considerably to that expense.
2. Ideally, the cost of ESRD therapy should be re ported as the cost incurred for all aspects of the treatment to the health-care system.
3. Most studies show peritoneal dialysis to be less expensive than hemodialysis, but this can vary depending on the local costs of supplies and labor.
4. Strategic decisions with regard to new innovations should be made after a full analysis of all of the involved costs and savings that the innovation might introduce.
5. Economic factors and reimbursement rates appear to have an important impact on modality selection.
PrichardS.Workshop on comparisons of CAPD with hemodialysis and transplantation. The cost of dialysis. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G. eds. Advances in CAPD.Toronto: Peritoneal Dialysis Bulletin Inc., 1988; 4: 66–9.
2.
MahoneyJ.F., KachelG.Comparative costs of dialysis in peritoneal dialysis. In: AtkinsR.C., ThomsonN.M., FarrellP.C. eds. Edinburgh, London: Churchill Livingstone, 1981: 418.
3.
DrummondM.F., StoddartG.L., TorranceG.W.Methods for the economic evaluation of health-care programmes.London: Oxford Medical Publications, 1987.
4.
Associazione Lombarda Provveditori Economi. 8up plemento La Dialisi al n. 2 del Notiziario ALE, 1992.
5.
SheingoldS., ChurchillD., MuirheadN.The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada.Soc Sci Med1993; 34(9): 983–91.
6.
NissensonA.R., PrichardS.S., ChengI.K.P.Non-medical factors that impact on ESRD modality selection.Kidney Int1993; 43(Suppl 40): 8120–7.
7.
PrichardS.Treatment modality selection: medical and non-medical factors. Submitted to the Ist International Symposium on Dialysis in Developing Countries. Singapore, April, 1995.
